Inspra /Eplerenone

ApprovedSmall molecule

Bayer

Inspra /Eplerenone is one of 110 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

RetinopathyActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

RetinopathyApproved

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Inspra /Eplerenone

Bayer

Approved

1 2

Byetta

AstraZeneca

Preclinical

20 3

Adenocard

Astellas

Preclinical

1 4

NOVOLIN R

Novo Nordisk

Preclinical

1 5

Dostinex

Cipro

Lantus

6 8

Lixisenatide

Sanofi

Preclinical

4 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Glargine

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV infection1 trial

Cardiometabolic Effects of Eplerenone in HIV Infection

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02629094·5 enrolled

Retinopathy1 trial

Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

Completed·SSemmelweis University·Phase 4·NCT02462499·28 enrolled

Type 2 Diabetes Mellitus1 trial

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Completed· Bayer logo

Bayer·Phase 2·NCT01807221·1,066 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Inspra /Eplerenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inspra /Eplerenone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inspra /Eplerenone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Inspra /Eplerenone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV infection1 trial

Retinopathy1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News